In their review article, Rahman and Isenberg (Feb. 28 issue)1 emphasize the role of anti–double-stranded DNA antibodies in the pathogenesis of systemic lupus erythematosus. Such antibodies also occur, however, in 23 to 64% of patients with type 1 autoimmune hepatitis, depending on the assay used.2 Interestingly, 36% of patients with type 1 autoimmune hepatitis and antibodies against double-stranded DNA have the HLA allele DR3, which is a genetic risk factor in both systemic lupus erythematosus and type 1 autoimmune hepatitis.3 However, there is no evidence of a pathogenic role of anti–double-stranded DNA antibodies in type 1 autoimmune hepatitis.
Pappas G, Granito A, Bianchi FB. (2008). Systemic lupus erythematosus. THE NEW ENGLAND JOURNAL OF MEDICINE, 358, 2411-2412 [10.1056/NEJMc080684].
Systemic lupus erythematosus.
GRANITO, ALESSANDRO;
2008
Abstract
In their review article, Rahman and Isenberg (Feb. 28 issue)1 emphasize the role of anti–double-stranded DNA antibodies in the pathogenesis of systemic lupus erythematosus. Such antibodies also occur, however, in 23 to 64% of patients with type 1 autoimmune hepatitis, depending on the assay used.2 Interestingly, 36% of patients with type 1 autoimmune hepatitis and antibodies against double-stranded DNA have the HLA allele DR3, which is a genetic risk factor in both systemic lupus erythematosus and type 1 autoimmune hepatitis.3 However, there is no evidence of a pathogenic role of anti–double-stranded DNA antibodies in type 1 autoimmune hepatitis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
